Regulation of Human Cytosolic Sulfotransferases (SULTs) 1C2 and 1C3 by Nuclear
Signaling Pathways in LS180 Colorectal Adenocarcinoma Cells

Elizabeth A. Rondini, Hailin Fang, Melissa Runge-Morris, and Thomas A. Kocarek

Institute of Environmental Health Sciences, Wayne State University, Detroit, MI 48201, USA

Running title: Regulation of SULTs 1C2 and 1C3 in LS180 cells

Address correspondence to: Dr. Thomas A. Kocarek, Institute of Environmental Health Sciences, 259 Mack Avenue, Room 4512, Wayne State University, Detroit, MI 48201, USA. Tel: (313) 577-6580; FAX: (313) 577-0082; E-mail: t.kocarek@wayne.edu

Number of text pages: 29
Number of tables: 0
Number of figures: 4 + 1 supplemental
Number of references: 39
Number of words in Abstract: 250
Number of words in Introduction: 697
Number of words in Discussion: 982

Abbreviations: ATRA, all-trans-retinoic acid; AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor (NR1H4); CDCA, chenodeoxycholic acid; Cipro, ciprofibrate; 9cRA, 9-cis-retinoic acid; CITCO, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime; Ct, cycle threshold; 1,25(OH)2D3, 1α,25-dihydroxyvitamin D3, DMSO, dimethyl sulfoxide; ERR, estrogen-related receptor (NR3B); FXR, farnesoid X receptor (NR1H4); LXRα, liver X receptor α (NR1H3); LXRβ, liver X receptor β (NR1H2); MEM, minimal essential medium; PPARα, peroxisome proliferator-activated receptor α (NR1C1); PPARγ, peroxisome proliferator-activated receptor γ (NR1C3); PXR, pregnane X receptor (NR1I2); PCR, polymerase chain reaction; qRT-PCR, quantitative reverse transcription-
polymerase chain reaction; RXR, retinoid X receptor, RXR (NR2B); RAR, retinoic acid receptor (NR1B); SDS, sodium dodecyl sulfate; SULT, cytosolic sulfotransferase; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TR, thyroid hormone receptor (NR1A); T3, 3,3',5'-triiodo-L-thyronine; VDR, vitamin D receptor (NR1I1).
ABSTRACT

Cytosolic sulfotransferases (SULTs) catalyze the sulfate conjugation of a myriad of endogenous and xenobiotic substrates. Among the 13 human SULTs, little is known regarding regulation of the SULT1C subfamily. We evaluated the effects of a panel of transcription factor activators on levels of SULT1C mRNA (1C2 and 1C3) and protein (1C2) in LS180 colorectal adenocarcinoma cells. Treatment with GW3965 [liver X receptor (LXR) activator], GW4064 [farnesoid X receptor (FXR)], or rifampicin [pregnane X receptor (PXR)] moderately (≤2-fold) increased both SULT1C2 and SULT1C3 mRNA levels. Vitamin D3 [(1,25(OH)2D3, vitamin D receptor (VDR)] selectively up-regulated SULT1C2, while ciprofibrate [peroxisome proliferator-activated receptor α (PPARα)], rosiglitazone (PPARγ), and 2,3,7,8-tetrachlorodibenzo-p-dioxin [Ah receptor (AhR)] selectively increased SULT1C3 mRNA levels. SULT1C2 protein content was strongly increased by 1,25(OH)2D3 treatment and moderately increased by GW3965, GW4064, and rifampicin. To evaluate SULT1C2 transcriptional regulation, treatment effects were determined on reporter activity from transfected constructs containing ~10 kb of the SULT1C2 gene. Treatment with GW3965, GW4064, or 1,25(OH)2D3 increased reporter activity ~2-, 5-, and 5.5-fold, respectively from a construct containing mostly intron 1 of the SULT1C2 gene. Expression of AhR, LXRα, LXRβ, PPARα, PPARγ, PXR, and VDR was confirmed in LS180 cells using qRT-PCR; however, FXR expression was negligible, suggesting that GW4064 increased SULT1C expression through an FXR-independent mechanism. Collectively our findings are the first to characterize the regulation of human SULT1C2 and SULT1C3 expression by several transcription factor activators. Further, we determined that responsive regions for LXR and VDR are likely contained within intron 1 of the SULT1C2 gene.
Introduction

Sulfotransferase enzymes catalyze the transfer of a sulfonate group from 3′-phosphoadenosine 5′-phosphosulfate to an accepting molecule (Strott, 2002). Two major classes of sulfotransferases have been identified. The membrane-bound sulfotransferases function on larger biomolecules, including proteins and carbohydrates, and play important roles in the maintenance of tissue structure and in cell signaling (Strott, 2002). In contrast, enzymes of the cytosolic sulfotransferase superfamily (SULTs) catalyze the phase II metabolism of xenobiotics as well as various endogenous molecules including cholesterol, sterol derivatives, neurotransmitters, and hormones (Strott, 2002). SULTs are widely expressed in both hepatic and extrahepatic tissues (Dooley et al., 2000). Generally, SULTs facilitate inactivation and elimination of compounds via the urine or bile and thus are important in detoxification processes (Gamage et al., 2006). Sulfonation reactions also regulate the synthesis and biological activity of a number of different hormones (Strott, 2002). However, as an undesirable effect, SULTs can catalyze the activation of promutagens into more mutagenic derivatives (Glatt, 2000).

A total of 13 SULT genes have been identified in humans that are grouped into 4 families (SULT1, 2, 4, and 6) based on amino acid sequence similarity (Blanchard et al., 2004). Most of the structural variation among SULTs occurs in the substrate-binding region, which is unique for each individual enzyme (Wang and James, 2006). Although there is some overlap in substrate specificity within family members, individual SULTs exhibit a characteristic expression pattern and can be distinguished somewhat based on their relative substrate affinities, thermal stability, and sensitivity to inhibitors (Nowell and Falany, 2006; Runge-Morris and Kocarek, 2009). In general, the SULT1 family members metabolize a range of phenolic substrates and include the
high-affinity catecholamine- (SULT1A2) and estrogen- (SULT1E1) sulfating enzymes, whereas the SULT2 family exhibits selectivity towards molecules with a steroid or sterol nucleus, such as dehydroepiandrosterone (SULT2A1), bile acids (SULT2A1), pregnenolone (SULT2B1a), and cholesterol (SULT2B1b) (Gamage et al., 2006; Lindsay et al., 2008). Substrate specificities for other human SULTs, including SULT1A2, SULT1B1, SULT1C2/C3/C4, SULT4A1, and SULT6B1, have not been well characterized (Lindsay et al., 2008; Runge-Morris and Kocarek, 2009; Runge-Morris et al., 2013).

Members of the human SULT1C subfamily are located in a cluster on chromosome 2q12 and have been among the less studied SULTs in terms of regulation and function. SULT1C2 (previously designated SULT1C1) was the first human SULT1C member to be cloned (Her et al., 1997). SULT1C2 mRNA was detected in adult stomach, kidney, and thyroid and in fetal liver and kidney (Her et al., 1997). SULT1C4 (previously designated SULT1C2) was later identified and found to be expressed at the mRNA level in adult spinal cord, kidney, and ovary and in fetal lung, heart, and kidney (Sakakibara et al., 1998). At the protein level, SULT1C4 was only detected in fetal tissues (Stanley et al., 2005). SULT1C2 and SULT1C4 both exhibited sulfonation activity towards \( p \)-nitrophenol and the promutagen \( N \)-hydroxy-2-acetylaminofluorene, suggesting a role in carcinogen activation (Sakakibara et al., 1998). Freimuth et al. (Freimuth et al., 2004) later predicted the existence of a third enzyme, SULT1C3, with 3 plausible splice variants (a, b, d) based on the arrangements of duplicated exons 7 and 8. Despite demonstrations that recombinant SULT1C3d exhibited sulfotransferase activity (Allali-Hassani et al., 2007; Meinh et al., 2008), neither SULT1C3 mRNA (Freimuth et al., 2004) nor protein (Meinh et al., 2008) was detectable in human tissues.
Regulation of the human SULT1C subfamily has not been previously studied. Several members of the nuclear receptor superfamily, including peroxisome proliferator-activated receptors (PPARs), constitutive androstane receptor (CAR), pregnane X receptor (PXR), vitamin D receptor (VDR), liver X receptor (LXR), and farnesoid X receptor (FXR), have been identified as transcriptional regulators of other SULT family members (Echchgadda et al., 2004; Fang et al., 2005; Jiang et al., 2005; Miyata et al., 2006; Echchgadda et al., 2007; Fang et al., 2007; Kodama et al., 2011). Using TaqMan primer/probes, we detected mRNA expression of SULT1C2 and SULT1C3 but not SULT1C4 in LS180 colorectal adenocarcinoma cells. Therefore, the purpose of this study was to evaluate the regulation of SULT1C2 and SULT1C3 using a panel of transcription factor activators. Additional studies were performed on SULT1C2 to assess treatment effects on protein levels as well as activation of cloned regions of the gene using reporter assays.
Materials and Methods

Chemicals and Reagents. Ciprofibrate (Cipro) was a gift from Sterling Winthrop Pharmaceuticals Research Division (Rensselaer, NY). GW3965 and GW4064 were purchased from Tocris Biosciences (Minneapolis, MN) and 2,3,7,8-tetrachlorodibenzo-\(p\)-dioxin (TCDD) from Midwest Research Institute (Kansas City, MO). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Cell culture medium, supplements, and Lipofectamine 2000 reagent were purchased from Invitrogen (Carlsbad, CA), TaqMan primer/probes from Applied Biosystems (Foster City, CA), SULT1C2 antibody (clone 5A) from Origene (Rockville, MD), \(\beta\)-actin antibody from Sigma-Aldrich, and horseradish peroxidase-conjugated secondary antibodies from Santa Cruz Biotechnology (Santa Cruz, CA). Additional materials were obtained from the sources indicated below.

Cell Culture and Treatments. LS180 cells were purchased from the American Type Culture Collection (Manassas, VA) and maintained in Minimal Essential Medium (MEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, MEM non-essential amino acids, 100 U/ml penicillin, and 100 \(\mu\)g/ml streptomycin. Cells were sub-cultured using 5 mM EDTA and seeded onto 12-well plates. Sixty hours following plating, transcription factor activators were added to the culture medium as concentrated (1000X) stock solutions dissolved in either DMSO [rifampicin (PXR), rosiglitazone (PPAR\(\gamma\)), GW3965 (LXR), GW4064 (FXR), chenodeoxycholic acid (CDCA, FXR), Cipro (PPAR\(\alpha\)), CITCO (CAR), 9-cis-retinoic acid (9cRA, RXR), all-trans-retinoic acid (ATRA, RAR), 3,3',5'-triiodo-L-thyronine (T3, TR), and TCDD (AhR)] or ethanol [1\(\alpha\),25-dihydroxyvitamin D3 (1,25(OH)\(\_\)\_D\(\_\)3, VDR)] at the concentrations indicated in the individual figure legends.
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). TaqMan primer/probes to detect SULT1C2 (Hs00602560_m1), SULT1C3 (Hs01371045_m1, Hs01371044_m1), AhR (Hs00169233_m1), CAR (Hs00901571_m1), FXR (Hs01026590_m1), LXRα (Hs00172885_m1), LXRβ (Hs00173195_m1), VDR (Hs01045847_m1), PXR (Hs01114267_m1), PPARα (Hs00947539_m1), PPARγ (Hs01115513_m1), and 18S rRNA were purchased from Applied Biosystems, and human reference cDNA was purchased from Clontech Laboratories (Mountain View, CA). The TaqMan primer/probe sets that were used to detect SULT1C3 mRNA targeted exons 3-4 (Hs01371045_m1) or exons 2-3 (Hs01371044_m1). Beginning 60 h after plating, cells (~50-60% confluency) were either left untreated or treated with vehicle or transcription factor activators at the concentrations indicated in the individual figure legends. Culture medium containing treatments was renewed once after 24 h. Forty-eight hours after the initial treatment, total RNA was extracted using RNeasy columns (Qiagen, Carlsbad, CA), and cDNA was synthesized from 1.5 µg total RNA using the High Capacity Reverse Transcription kit (Applied Biosystems). Quantitative determination of mRNA levels was performed with the StepOne Plus Real Time PCR System (Applied Biosystems) using Gene Expression Master Mix (Applied Biosystems), 50 ng RNA equivalents of reverse transcription reactions, and TaqMan primer/probes. The cycling conditions were as follows: PCR initial activation step at 95°C for 15 min and a total of 40 cycles for melting (95°C, 15 s) and annealing/extension (60°C, 1 min). Assays were performed in duplicate and were repeated in at least three independent cell culture experiments for SULT1C and two experiments for transcription factors. Relative fold-changes in SULT1C2 and SULT1C3 mRNA levels were quantified by using the comparative Ct (ΔΔCt) method (User bulletin no.2, Applied Biosystems).
and are expressed as fold-change relative to vehicle-treated control. For transcription factor assays, the cycle threshold (Ct) was compared to that of a human reference cDNA standard.

**Immunodetection of SULT1C2 by Western blotting.** LS180 cells were plated onto 12-well plates and treated with select nuclear receptor activators as described above. Forty-eight hours after the initial treatment, cells were scraped and pelleted at 1,000 x g for 5 min in ice-cold phosphate-buffered saline. Whole cell lysates were prepared by sonicating cell pellets in ice-cold RIPA buffer (50 mM Tris, 150 mM NaCl, 0.2% SDS, 0.25% sodium deoxycholate, 1% Triton X-100, 1 mM EDTA) containing protease inhibitors (Thermo Fisher, Rockford, IL). Lysates were centrifuged at 13,000 x g for 15 min at 4°C, and the protein concentrations of the supernatants were measured using the bicinchoninic acid protein assay (Sigma-Aldrich). Proteins (15 µg) were resolved on 12.5% SDS-polyacrylamide gels and then transferred onto polyvinylidene difluoride membranes (BioRad, Hercules, CA). Following transfer, membranes were incubated in blocking buffer (2.5% nonfat dry milk dissolved in 20 mM Tris-buffered saline (pH 7.4) containing 0.05% Tween-20) for 1 h at room temperature and then probed with anti-SULT1C2 antibody (1:2,000) diluted in blocking buffer overnight at 4°C. After washing in 20 mM Tris buffer (pH 7.4) containing 0.05% Tween-20, blots were incubated with secondary antibody (1:25,000) linked to horseradish peroxidase for 1 h at room temperature, and immunoreactive bands were detected using enhanced chemiluminescence. Images were captured on radiographic film (GE Healthcare Biosciences, Pittsburg, PA). Following detection, membranes were stripped in glycine stripping buffer (pH 2.2) and re-probed for β-actin using the procedures described above. Films were subsequently scanned and band densities were quantified using ImageJ software (Rasband, 2012).
Preparation of SULT1C2 reporter plasmids and transient transfection of LS180 cells.

Two constructs of the SULT1C2 gene spanning ~10 kb upstream of the translation start site were prepared by PCR using human genomic DNA as a template, HotStar HiFidelity Polymerase (Qiagen, Valencia, CA), and primers corresponding to nt 108,900,218 to 108,900,239 (5'-GGGGGTACCAGAGATGAGTATGGCTAACCACA-3') and 108,905,209 to 108,905,186 (5'-GGGGCTAGCTCATATGAACTAAGGGCACACTCT-3') of NCBI chromosome 2 reference sequence NC_000002.11 for construct SULT1C2#1 and nt 108,905,126 to 108,905,145 (5'-GGGGGTACCCAGGCAGCTGAGGGCCAGGA-3') and 108,910,123 to 108,910,104 (5'-GGGGCTAGCGAGTCTCAGGGTTGGGTC-3') for construct SULT1C2#2. The underscored nucleotides of the primers indicate restriction sites for ligation into the pGL4.24[luc2P/minP] firefly luciferase reporter plasmid (Promega Corporation, Madison, WI), which contains a minimal promoter. Construct SULT1C2#1 is 4992 base pairs in size, spans nt -9906 to -4915 relative to the translation start site, and contains mostly 5’-flanking region of the SULT1C2 gene (Freimuth et al., 2000). SULT1C2#2 (4998 base pairs) spans nt -4998 to -1 relative to the translation start site and contains all of intron 1 and most of the non-coding exon 1 of the SULT1C2 gene (Freimuth et al., 2000). The sequences of all cloned fragments were verified by the Applied Genomics Technology Center at Wayne State University.

To determine the abilities of transcription factor activators to regulate SULT1C2 transcription, LS180 cells were transiently transfected with each of the reporter constructs. Following plating (~60-70% confluency), culture medium was replaced with 0.2 mL of Opti-MEM containing a premixed complex of 4 µL of Lipofectamine 2000, 1.6 µg of SULT1C2 reporter plasmid, and 1 ng of a Renilla luciferase reporter plasmid driven by a cytomegalovirus promoter (Promega Corporation) to allow for normalization. Plates were incubated in
transfection medium for 5 h, after which the medium was replaced with MEM. The following
day, fresh medium, either alone or containing a transcription factor activator was added to each
well, as described in the individual figure legends. Medium was replaced once after 24 h. Cells
were harvested for measurement of luciferase activities 48 h following initial treatment using the
Dual Luciferase Reporter Assay System and a GloMax luminometer (Promega), each according
to the manufacturer’s instructions. Data are expressed as normalized fold-changes relative to
vehicle-treated controls. All treatments were performed in triplicate and repeated at least 3
independent times.

**Statistical Analysis.** Statistical analyses were performed using GraphPad Prism software
(Version 4; La Jolla, CA). Data for Western blotting were analyzed using one-way analysis of
variance (ANOVA), and when statistical differences were detected with the F statistic \( P<0.05 \),
individual comparisons were made using the Student-Newman-Keuls test. Data for qRT-PCR
and transient transfections were analyzed using the Kruskal-Wallis test followed by Dunn’s
multiple comparison test. All results were considered significant at \( P<0.05 \) and are presented as
mean ± S.E.M.
Results

Regulation of SULT1C2 and SULT1C3 expression by transcription factor activators.

To determine the transcriptional regulation of SULT1C2 and SULT1C3, LS180 colorectal adenocarcinoma cells were initially treated with a panel of 12 prototypical transcription factor activators at varying concentrations for 48 h and the relative mRNA levels of SULT1C2 and SULT1C3 were assessed by qRT-PCR. Results are presented in Figure 1. Treatment with 10 μM GW4064 (FXR), 10 μM GW3965 (LXR), or 30-50 μM rifampicin (PXR) moderately (≤ 2-fold increase) increased the mRNA levels of both SULT1C2 and SULT1C3 compared to DMSO-treated controls (P<0.05). Treatment with 1,25(OH)2D3 (VDR) strongly and selectively increased SULT1C2 mRNA levels over a wide concentration range (0.001-0.1 μM), whereas Cipro (100 μM, PPARα), TCDD (0.01 μM, AhR), and rosiglitazone (0.01-10 μM, PPARγ) were selective inducers of SULT1C3 mRNA (Figure 1; P<0.05). No significant changes in mRNA levels were observed for any of the other nuclear receptor activators (CDCA, CITCO, T3, ATRA, and 9cRA) at the concentrations tested. Because initial attempts to identify SULT1C3 expression in human tissue samples were unsuccessful (Freimuth et al., 2004) and the potential existence of splice variants has been suggested (Freimuth et al., 2004), we further evaluated SULT1C3 mRNA levels using an additional primer/probe set spanning exons 2-3 (Supplemental Figure 1). We found comparable induction of SULT1C3 mRNA by GW4064 (10 μM), GW3965 (10 μM), rifampicin (30-50 μM), Cipro (100 μM), TCDD (0.01 μM), and rosiglitazone (0.01-10 μM) with both primer/probe sets tested, further strengthening our findings on SULT1C3 transcriptional regulation.
SULT1C2 protein is induced by select nuclear receptor activators in LS180 cells. Changes in SULT1C2 expression were further evaluated at the protein level by Western blotting and results are presented in Figure 2. In general, 1,25(OH)₂D₃ (0.001-0.1 μM), GW4064 (10-30 μM), GW3965 (10 μM), and rifampicin (30-50 μM) all induced SULT1C2 protein levels, consistent with the changes observed for mRNA. However, the magnitude of change induced by 1,25(OH)₂D₃ was larger than that observed for mRNA, with a ~5-fold increase at the highest concentration tested (0.1 μM, Figure 2A). Despite the increase observed with GW4064, CDCA, a physiological ligand for FXR, did not significantly alter SULT1C2 protein levels compared to vehicle-treated control (Figure 2E).

Activation of SULT1C2 reporter constructs by nuclear receptor activators. Additional experiments were conducted to evaluate the transcriptional regulation of SULT1C2 by testing whether FXR, LXR, VDR, and PXR agonists could alter the expression of a luciferase reporter driven by gene sequences located within ~10 kb upstream of the SULT1C2 translation start site. Construct SULT1C2#1 (4992 nt) contains mostly 5’-flanking region of the SULT1C2 gene, whereas SULT1C2#2 (4998 nt) begins at nucleotide -1 relative to the translation start site and contains all of intron 1 and most of the non-coding exon 1 of the SULT1C2 gene. LS180 cells were transiently transfected with each reporter plasmid, and luciferase activities were measured 48 h after treatment with activators. As shown in Figure 3, we found that most of the nuclear receptor responsive elements are contained within construct #2 (Figure 3B). Consistent with results for mRNA and protein expression, treatment of cells with either 1,25(OH)₂D₃ (0.1 μM), GW4064 (10 μM), or GW3965 (10 μM) significantly increased luciferase reporter activity from construct SULT1C2#2 compared to the vehicle-treated control (P<0.05), whereas only GW4064 (10 μM) increased the activity of SULT1C2#1 (Figure 3A). However, despite the changes
observed at the mRNA and protein level by rifampicin, no significant effect on reporter activity for either construct was observed. CDCA also failed to induce luciferase expression compared to vehicle-treated control.

**Expression of nuclear receptors and AhR in LS180 cells.** LS180 cells have been previously suggested to be a good model for studying PXR- and VDR-responsive gene expression (Gupta et al., 2008; Meyer et al., 2012). However, given a report that GW4064 is also an agonist for estrogen-related receptor (ERR) α, β, and γ (Dwivedi et al., 2011) and additional evidence that FXR mRNA and protein are expressed at low levels in several colon cancer cell lines (Torres et al., 2013), we evaluated the basal expression of FXR and other transcription factors in LS180 cells compared to a commercial human reference cDNA standard synthesized from RNA collected from a mixture of normal human adult tissues. We found that AhR, LXRα, LXRβ, PPARα, PPARγ, PXR, and VDR were all basally expressed in LS180 cells at levels comparable to or higher than that detected in the human reference cDNA standard (Figure 4). Consistent with a previous report (Gupta et al., 2008), CAR was negligibly expressed in LS180 cells. Also, FXR expression was barely detectable (Ct=38) compared to the reference standard (Figure 4).
Discussion

Enzymes of the SULT superfamily are involved in the metabolism of xenobiotics and endogenous compounds as well as in modulating the biological activities of hormones (Strott, 2002). Given their diverse roles, evaluating the expression and regulation of SULTs has implications for understanding individual responses to pharmacological and toxicological agents as well as in disease etiology (Wang et al., 2002; Suzuki et al., 2003; Cotterchio et al., 2008; Hirata et al., 2008). The regulation of endogenous substrates for the SULT1C subfamily have not been well characterized. Nuclear receptors have been demonstrated to regulate several human, murine, and rat SULTs [reviewed in (Runge-Morris et al., 2013)]. Therefore the purpose of the current study was to determine if similar molecular signals also regulate expression of the SULT1C enzymes.

Transcriptional responses of SULT1C2 and SULT1C3 were evaluated by treating LS180 cells with prototypical transcription factor activators. Our results indicate both common and selective regulation of SULT1C expression. For example, activators of PXR (rifampicin), LXR (GW3965), and FXR (GW4064) moderately induced the mRNA levels of both SULT1C enzymes. However, whereas SULT1C2 expression was strongly up-regulated by 1,25(OH)\textsubscript{2}D\textsubscript{3}, SULT1C3 mRNA levels were unaffected. Conversely, activators of AhR (TCDD), PPAR\textsub{\alpha} (Cipro), and PPAR\textsub{\gamma} (rosiglitazone) were selective in inducing the expression of SULT1C3. These selective effects imply both contextual and non-overlapping regulation of these enzymes. Other prototypical activators including CDCA (FXR), 9cisRA (RXR), ATRA (RAR), and CITCO (CAR) did not influence SULT1C expression. Additionally, although SULT1C2 is expressed in thyroid tissue (Her et al., 1997) and exhibits activity towards iodothyronines in vitro (Li et al., 2000), neither SULT1C2 nor SULT1C3 was regulated by T3 in LS180 cells.
Treatment effects on SULT1C2 were further investigated using Western blotting and reporter assays. SULT1C2 protein levels were increased by rifampicin, GW4064, and GW3965 and strongly up-regulated by 1,25(OH)₂D₃, whereas no significant effect on SULT1C2 protein content was observed with CDCA. Effective concentrations of GW4064, GW3965, and 1,25(OH)₂D₃ also increased reporter activity from a construct containing intron 1 and most of the non-coding exon 1 of the SULT1C2 gene. Computational analysis of the SULT1C2#2 sequence for potential transcription factor binding sites using MatInspector (Cartharius et al., 2005) identified four matches (matrix similarity greater than optimized matrix threshold) to LXR•RXR binding sites (i.e., MatBase matrices V$LXRE.01 and V$LXRE.02) and ten matches to VDR•RXR binding sites (i.e., matrices V$VDR_RXR.03, V$VDR_RXR.04, V$VDR_RXR.05, and V$VDR_RXR.06), supporting the likelihood that detailed analysis of this SULT1C2 gene region will lead to the identification of functional LXR and VDR response elements.

GW4064 is widely used as a selective agonist for evaluating FXR-mediated responses, although additional reports imply agonist-specific responses in addition to those mediated by FXR (Downes et al., 2003; Pircher et al., 2003; Dwivedi et al., 2011). The effect of GW4064 observed in this study was generally modest at the mRNA level for SULT1C2 and SULT1C3. We did observe a concentration-dependent induction of SULT1C2 protein by Western blotting and strong activation of both SULT1C2 reporter constructs. However, treatment with CDCA, an endogenous ligand for FXR, did not elicit similar responses. This, together with the low basal expression of FXR in LS180 cells, implies that the effects of GW4064 on SULT1C expression are likely not FXR-mediated. The target for GW4064-mediated SULT1C regulation in this study was not conclusively determined. Based on findings by Dwivedi et al. (Dwivedi et al., 2011), attempts were made to reduce basal luciferase activity of the SULT1C2 constructs using
XCT790, an inverse ERRα agonist, or increase expression with GSK4716, an activator of both ERRβ and γ (data not shown) (Zuercher et al., 2005). We found that 5 μM XCT790, a concentration that produced maximal inhibition in the study by Dwivedi et al. (Dwivedi et al., 2011), did not inhibit, but rather slightly increased, luciferase activity on construct #2. Additionally, GSK4716 did not significantly augment reporter activity at a concentration up to 5 μM. Therefore, although we cannot rule out a potential involvement of FXR and/or ERR on SULT1C2 regulation, the effects of GW4064 observed in this study do not appear to be directly mediated through either receptor.

Findings that SULT1C3 is expressed and regulated in LS180 cells are novel given the paucity of information available on this subfamily member. SULT1C3 was originally identified through computational analyses with 3 plausible splice variants (a, b, d) predicted based on the arrangements of duplicated exons 7 and 8 (Freimuth et al., 2004). Subsequent studies using a recombinant protein for SULT1C3d (containing exons 7b and 8b) demonstrated that this variant exhibited sulfotransferase activity in vitro and activated promutagens in an Ames assay (Meinl et al., 2008), although neither mRNA nor protein was detectable in human tissues (Freimuth et al., 2004; Meinl et al., 2008). In a concurrent study (Duniec-Dmuchowski et al., submitted) we report that the predominant transcript expressed in LS180 and intestinal cells is SULT1C3a (containing exons 7a and 8a). It should be noted that the primers used in the current study target more upstream (exons 2-3 and 3-4) regions of SULT1C3 mRNA and are therefore likely to detect all splice variants, if present. Although we found SULT1C3a to be expressed and transcriptionally regulated in this cell line, it is possible that other SULT1C3 splice variants are expressed in different tissues or at different times during development.
The intestine is exposed to numerous compounds derived from the diet and environment, as well as to endogenous and bacterial metabolites. In humans, SULT enzymes are highly expressed in intestinal tissue, with SULT1B1, 1A3, and 1A1 the major members detected (Riches et al., 2009). In the current study, we identified that SULT1C2 and SULT1C3 are additionally expressed in intestinal cells and are regulated by select ligand-dependent transcription factors. Additional detailed promoter analysis, mutational studies, and binding assays will more conclusively determine the specific regulatory elements for both enzymes. Our findings will guide future research that is designed to understand the regulation and physiological role of the SULT1C class of enzymes.
Authorship Contributions

Participated in research design: Rondini, Runge-Morris, Kocarek

Conducted experiments: Rondini

Contributed new reagents or analytic tools: Fang

Performed data analysis: Rondini

Wrote or contributed to the writing of the manuscript: Rondini, Runge-Morris, Kocarek


Footnotes

This research was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grant R01 HL050710] (to T.A.K.) and National Institute of Environmental Health Sciences [Grant R01 ES005823] (to M.R.-M.).
Figure Legends

**Fig. 1.** Effects of transcription factor activators on (A) SULT1C2 and (B) SULT1C3 mRNA levels in LS180 cells. LS180 cells were sub-cultured onto 12-well plates and 60 h later were treated with nuclear receptor activators at the indicated concentrations. DMSO (0.1%) and ethanol (0.1%) were used as vehicle controls. Medium containing the drug treatments was replaced once after 24 h. Forty-eight hours following initial treatment, cells were harvested and relative mRNA levels of SULT1C2 and SULT1C3 were quantified by qRT-PCR. The SULT1C3 TaqMan assay targeted exons 3-4. All assays were performed in duplicate and repeated at least three independent times (n=6-26/treatment). Bars represent mean ± S.E.M. *Significantly different from DMSO-treated control (P<0.05); †significantly different from ethanol-treated control (P<0.05).

**Fig. 2.** Effects of select nuclear receptor activators on SULT1C2 protein levels in LS180 cells. LS180 cells were sub-cultured onto 12-well plates and 60 h later treated with medium containing either (A) 1,25(OH)2D3 (VDR), (B) rifampicin (PXR), (C) GW3965 (LXR), (D) GW4064 (FXR), or (E) CDCA (FXR) at the indicated concentrations. DMSO (0.1%) and ethanol (0.1%) were used as vehicle controls. Medium containing the drug treatments was replaced once after 24 h. Forty-eight hours following the initial treatment, whole cell lysates were prepared and SULT1C2 protein levels were determined by Western blotting. β-Actin was used as a loading control. Shown are representative images from 2-3 independent experiments. The densities of bands were quantified using ImageJ software and values normalized to vehicle-treated controls.
Bars represent mean ± S.E.M. (n=4-6/treatment). *Significantly different from vehicle-treated controls (P<0.05).

**Fig. 3.** Modulation of SULT1C2 reporter activity by select nuclear receptor activators. Two regions of the SULT1C2 gene spanning ~10 kb upstream of the translation start site (construct SULT1C2#1 (nt -9906 to -4915 relative to the translation start site) and SULT1C2#2 (nt -4998 to -1) were PCR-amplified and ligated into the pGL4.24 luciferase reporter plasmid. LS180 cells were sub-cultured onto 12 well plates and 60 h after plating were transfected with the reporter plasmids as described in Materials and Methods. The following day, medium containing nuclear receptor activators at the indicated concentrations was added to the wells. Medium containing treatments was replaced once after 24 h. Ninety-six hours after initial plating, cells were harvested for the measurement of luciferase activity. Bars represent the mean ± S.E.M. of normalized luciferase measurements (Firefly/Renilla) combined from at least 2 independent experiments (n=3 wells/treatment/experiment). *Significantly different from DMSO-treated control (P<0.05); †significantly different from ethanol-treated control (P<0.05).

**Fig. 4.** Expression of select nuclear receptors and AhR in LS180 cells compared to a human reference cDNA standard. LS180 cells were sub-cultured onto 12-well plates and 108 h later, RNA was isolated and cDNA synthesized as described in Materials and Methods. Basal expression of select nuclear receptors and AhR was assessed in LS180 cells compared to a human reference cDNA standard (Ref) using TaqMan qRT-PCR assays. End-point PCR products (20 μL) were resolved on 2% agarose gels, and ethidium bromide-stained bands were visualized.
using an ultraviolet transilluminator. Shown are representative images. Values represent mean Ct from two independent experiments (n=2-6/group).
Relative SULT1C2 mRNA Levels

Relative SULT1C3 mRNA Levels

Fig. 1
Fig. 2

A

Relative Fold Change (SULT1C2/β-Actin)

ETOH 0.0001 0.001 0.01 0.1 μM

1,25(OH)₂D₃

B

Relative Fold Change (SULT1C2/β-Actin)

DMSO 10 30 50 μM

Rifampicin

C

Relative Fold Change (SULT1C2/β-Actin)

DMSO 3 10 30 μM

GW3965

D

Relative Fold Change (SULT1C2/β-Actin)

DMSO 3 10 30 μM

GW4064

E

Relative Fold Change (SULT1C2/β-Actin)

DMSO CDCA (100 μM)
Fig. 3

A

hSULT1C2 Construct #1
Relative Fold Change (Firefly/Renilla)

DMSO GW3965 GW4064 Rifampicin ETOH 1,25(OH)2D3 CDCA
(10 μM) (10 μM) (100 μM) (30 μM) (0.1 μM)

B

hSULT1C2 Construct #2
Relative Fold Change (Firefly/Renilla)

DMSO GW3965 GW4064 Rifampicin ETOH 1,25(OH)2D3
(10 μM) (10 μM) (100 μM) (30 μM) (0.1 μM)
**Fig. 4**

<table>
<thead>
<tr>
<th></th>
<th>LS180</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>AhR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ct:</td>
<td>25</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>28</td>
</tr>
<tr>
<td>CAR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ct:</td>
<td>38</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>28</td>
</tr>
<tr>
<td>FXR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ct:</td>
<td>38</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>33</td>
</tr>
<tr>
<td>LXRα</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ct:</td>
<td>28</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>28</td>
</tr>
<tr>
<td>LXRβ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ct:</td>
<td>29</td>
<td>28</td>
</tr>
</tbody>
</table>

This article has not been copyedited and formatted. The final version may differ from this version.